Non-energy devices to dissect recurrent laryngeal nerve lymph nodes of non-small cell lung cancer under video-assisted thoracic surgery

Minhao Yu1 and Mingjian Ge2*

Abstract

Background: Systematic nodal dissection plays a crucial role in improving survival and staging in resectable non-small cell lung cancer (NSCLC) patients, but at the cost of increasing the occurrence of recurrent laryngeal nerve injury. Technology should be improved to protect the recurrent laryngeal nerve (RLN) during surgery.

Methods: NSCLC patients who underwent video-assisted thoracic surgery (VATS) surgical treatment by the same surgeon at our hospital from January 2016 to December 2017 were included as the research subjects and were divided into an energy-device group and a non-energy-device group. Their procedures included anatomic pulmonary resection, normative N1 dissection, and systemic N2 dissection.

Results: The rate of metastatically involved recurrent laryngeal nerve lymph nodes (RLNLNs) was 5.19% (39/752). Dissection device, side of primary, FEV1, operative time and BMI were independent predictors of recurrent laryngeal nerve injury (RLNI) (hazard ratio (HR) = 3.576, 95% confidence interval (CI): 1.490–8.583, P = 0.004; HR = 0.175, 95% CI: 0.072–0.424, P < 0.001; HR = 3.008, 95% CI: 1.30–6.927, P = 0.010; HR = 0.328, 95% CI: 0.136–0.794, P = 0.013; HR = 0.344, 95% CI: 0.147–0.801, P = 0.013, respectively). Patients in the non-energy-device group had significantly less RLNI than the energy-device group (P = 0.016) and nearly half of the non-thermal RLNI recovered in 2 weeks (P = 0.025) whereas most thermal RLNI required 3 months for recovery.

Conclusions: Every station of RLNLN had some degree of cancer metastasis in NSCLC patients, and when dissecting RLNLNs, dissection device was an independent and artificially controlled predictor of RLNI. Using a non-energy device is a feasible method to protect the RLN as well as an improved recovery time of RLNI.

Keywords: Non-small cell lung cancer, Recurrent laryngeal nerve injury, Non-energy device, Systematic nodal dissection

Background

Lung cancer was the most common incident cancer and the leading cause of cancer death in China in 2015, with a total of 733,300 new cases and 610,200 deaths [1]. For patients with resectable non-small cell lung cancer (NSCLC), complete resection should be performed, and to achieve a radical resection, systematic nodal dissection (SND) is essential. A study from Wu et al. concluded...
lobectomy combined with SND can improve survival in resectable NSCLC, especially for patients in Stage I and Stage IIIA [2]. Although some researchers have reported that lobe-specific lymph node dissection has the potential to be a standard procedure in the surgical treatment of NSCLC [3], Maniwa et al. [4] found that recurrence of metastatically involved mediastinal nodes in patients undergoing lobe-specific nodal dissection was significantly greater than those undergoing SND. Wen et al. [5] also provided evidence that at least 12 locations of lymph nodes should be examined to provide longer 5-year cancer-specific survival and a significant reduction in disease recurrence in patients with T2N0 NSCLC. Additionally, SND is also important for disease staging. Alastair et al. [6] postulated that because no clinical or pathologic subset of patients could be identified that had a negligible incidence of N2 disease, SND should be routinely undertaken for accurate intrathoracic staging of NSCLC. Even though there are alternative sampling technologies, such as EBUS-TBNA and mediastinoscopy, a Dutch study showed that increased usage of less invasive endosonography prior to or even substituting for surgical staging did not uncover unexpected cases of N2 nodal disease in NSCLC [7], therefore, the greater the number of resected lymph nodes, the less likely N1 or N2 disease would be incorrectly diagnosed as N0 [5]. Furthermore, in Liu’s study, the incidences of upstaging from N0 to N1 and N2 disease were 7.7% and 12.2% utilizing SND [8].

Nevertheless, the role of SND in the treatment of NSCLC remains controversial, because a more thorough lymph node dissection typically increases the occurrence of postoperative complications. These include bleeding, cardiac arrhythmias, chylothorax, bronchopleural fistula and recurrent laryngeal nerve injury (RLNI). When dissecting the recurrent laryngeal nerve lymph nodes (RLNLNs), defined as 2R, 3p, 4L and 5 lymph nodes, the recurrent laryngeal nerve (RLN) may be damaged with significant neurological consequences. A study from Ewald et al. [9] verified that all unintentional injuries of the RLN were associated with mediastinal lymph node dissection (MLND). Watanabe et al. [10] reviewed their technique and experience of MLND, and found their incidence of RLNI to be 1.5%. Notably, they performed all MLND using thermal technology including conventional electrocautery or ultrasonic scalpel. Experimentally, a decrease in RLNI was reported with the implementation of the vessel sealing system (VSS) when compared with conventional scissors [10]. But no further investigation evaluated the risk factors for RLNI.

Because it was our impression from our own experience, that RLNI was infrequent using traditional non-energy devices, we tested this hypothesis by retrospectively examining the frequency of RLNI following RLNLN dissection using either “energy” and “non-energy” devices, during NSCLC surgery.

**Materials and methods**

**Patients**

Included were selected NSCLC patients who underwent surgical treatment by the same surgeon at The First Affiliated Hospital of Chongqing Medical University, China from January 2016 to December 2017, divided into an energy-device group and a non-energy-device group. In addition to this, we confirm that all methods were performed in accordance with the relevant guidelines and regulations. The inclusion criteria were as follows: NSCLC patients with clinically early (cT1a-2bN0-1M0) and advanced (cT3-4N0-1MO) stage disease, without invasion of surrounding tissues, who underwent surgical treatment via video-assisted thoracic surgery (VATS). Exclusion criteria were as follows: preoperative hoarseness or choking, neoadjuvant therapy, intraoperative RLNLN calcification and fusion, intraoperative tumor or metastatic lymph node invasion of the RLN; intrathoracic extensive adhesions or pleural cavity atresia, non-anatomical lung resection, and segmentectomy. The final study group comprised 188 patients.

**Surgical methods**

Using a VATS approach, all patients underwent anatomic pulmonary resection, normative N1 dissection, and systemic N2 dissection. The dissection zones of the right N2 lymph node included 2R, 3a, 3p, 4R, 7, 8R, and 9R, whereas the left dissection zones included 4L, 5, 6, 7, 8L, and 9L. The energy-device group underwent RLNLNs dissection using energy devices such as an electric hook or electrotome. In the non-energy-device group, devices such as tissue scissors or endoscopic scissors were used. In both groups, the initial dissection exposed the motor and sensory branches of the RLN, and the motor branches were carefully protected. The sensory branches were transected to expose the deep lymph node mass. During dissection, the RLN was kept in place to avoid mechanical stretch.

**Determination of RLNI**

The occurrence of RLNI was determined by the clinical presence of postoperative hoarseness and/or choking.

**Statistical analysis**

SPSS 22.0 (IBM Corp., Armonk, NY, USA) software was used for the statistical analysis. Continuous data were expressed as the mean ± standard deviation. A t-test was used to compare normally distributed data according to whether the variance was equal or not. The Mann–Whitney U test was used to compare
non-normally distributed data sets. Categorical data were expressed as counts and percentages, and comparisons between groups were performed using the chi-square test or the Fisher exact probability method. Indicators with statistically significant results from univariable analysis were incorporated into a logistic regression model for multivariable analysis to screen for the risk factors of RLN injury. We used Propensity Scores Matching (PSM) to adjust selection bias. The difference was statistically significant at $P < 0.05$.

**Results**

**Patients characteristics**

Of the 188 NSCLC patients, there were 119 men and 69 women. The age, body mass index (BMI), forced expiratory volume in 1 s (FEV1), location of primary, lobar origin, stage, mean tumor diameter and blood loss between the two groups were not significantly different, whereas the operative time in the non-energy-device group was significantly lower than the energy-device group ($P = 0.006$). The clinical characteristics of the two groups are shown in Table 1.

### Table 1 Comparison of clinical characteristics between the two groups

| Clinical characteristics          | Groups                                | P value |
|----------------------------------|---------------------------------------|---------|
|                                  | Non-energy device (n=96)               | Energy device (n=92) |         |
| Age (years)                      | 60.55±9.82                           | 60.84±9.32 | 0.839   |
| Gender                           |                                       |          |
| Male                             | 58 (30.85%)                           | 61 (32.45%) | 0.450   |
| Female                           | 38 (20.21%)                           | 31 (16.49%) |         |
| BMI                              | 22.92±3.12                            | 23.39±3.57 | 0.347   |
| FEV1                             | 2.36±0.58                             | 2.27±0.66  | 0.384   |
| Location of primary              |                                       |          |
| Peripheral                       | 80 (42.55%)                           | 69 (36.70%) | 0.208   |
| Central                          | 16 (8.51%)                            | 23 (12.23%) |         |
| Lobar origin                     |                                       |          |
| RUL                              | 19 (10.11%)                           | 32 (17.02%) | 0.277   |
| RML                              | 12 (6.38%)                            | 5 (2.66%)  |         |
| RLL                              | 16 (8.51%)                            | 14 (7.45%)  |         |
| RMLL                             | 0 (0%)                                | 2 (1.06%)  |         |
| Right hilum                      | 1 (0.53%)                             | 2 (1.06%)  |         |
| LUL                              | 33 (17.55%)                           | 18 (9.57%)  |         |
| LLL                              | 15 (7.98%)                            | 16 (8.51%)  |         |
| Left hilum                       | 0 (0%)                                | 3 (1.60%)  |         |
| pTNM stage                       |                                       |          |
| IA                               | 35 (18.62%)                           | 17 (9.04%)  | 0.084   |
| IB                               | 19 (10.11%)                           | 26 (13.83%) |         |
| IIA                              | 5 (2.66%)                             | 6 (3.19%)   |         |
| IIB                              | 14 (7.45%)                            | 13 (6.91%)  |         |
| IIIA                             | 15 (7.98%)                            | 19 (10.11%) |         |
| IIIB                             | 2 (1.06%)                             | 9 (4.79%)   |         |
| IIIC                             | 1 (0.53%)                             | 0 (0%)     |         |
| IVA                              | 4 (2.13%)                             | 3 (1.60%)  |         |
| Mean tumor diameter (cm)         | 3.21±1.92                             | 3.30±1.45  | 0.736   |
| Operative time (min)             | 154.98±43.07                          | 172.83±44.96 | 0.006   |
| Blood loss (ml)                  | 216.76±148.06                         | 188.37±105.7 | 0.133   |
| Chest tube drainage (ml)         | 117.62±51.34                          | 104.86±50.29 | 0.352   |
| Duration with tube (day)         | 5.49±3.82                             | 3.97±3.27  | 0.531   |
| RLNI                             | 12 (6.38%)                            | 25 (13.30%) | 0.016   |

BMI: body mass index, FEV1: forced expiratory volume in 1 second, RUL: right upper lobe, RML: right middle lobe, RLL: right lower lobe, RUL: right upper-middle lobe, RMLL: right middle-lower lobe, LUL: left upper lobe, LLL: left lower lobe, RLNI: recurrent laryngeal nerve injury
Rate of metastatically involved RLNLNs
Four RLNLN stations were dissected in all 188 patients for a total of 752 stations. Pathologically confirmed metastatic RLNLNs were found in 39 stations from 37 patients, yielding a metastatic rate of 5.19% (39/752, Table 2).

Table 2 Metastatic rate of RLNLNs

| Station | n | Metastatic rate |
|---------|---|-----------------|
| 2R      | 15| 1.99% (15/752)  |
| 3p      | 3 | 0.40% (3/752)   |
| 4L      | 10| 1.33% (10/752)  |
| 5       | 11| 1.46% (11/752)  |
| Total   | 39| 5.19% (39/752)  |

Table 3 Univariable analysis of RLNI pre- and post-PSM

|                   | RLNI (pre-PSM) | P value | RLNI (post-PSM) | P value |
|-------------------|---------------|---------|-----------------|---------|
|                   | Yes (n=37)    | No (n=151) |                  | Yes (n=24) | No (n=24) |        |
| Dissection device | Energy        | 25 (13.30%) | 67 (35.64%) | 0.016 | 11 (22.92%) | 3 (6.28%) | 0.008 |
|                   | Non-energy    | 12 (6.38%)  | 84 (44.69%) |        | 13 (27.08%) | 21 (43.75%) |        |
| Side of primary   | Left          | 26 (13.83%) | 59 (31.38%) | 0.001 | 8 (16.67%)  | 8 (16.67%) | < 0.001 |
|                   | Right         | 11 (5.85%)  | 92 (48.94%) |        | 16 (33.33%) | 16 (33.33%) |        |
| Age (years)       | < 60          | 20 (10.64%) | 61 (32.45%) | 0.143 | 12 (25.00%) | 16 (33.33%) | 0.506 |
|                   | > 60          | 17 (9.04%)  | 90 (47.87%) |        | 12 (25.00%) | 8 (16.67%)  |        |
| Gender            | Male          | 22 (11.70%) | 97 (51.60%) | 0.704 | 16 (33.33%) | 15 (31.25%) | 0.806 |
|                   | Female        | 15 (7.98%)  | 54 (28.72%) |        | 8 (16.67%)  | 9 (18.75)  |        |
| FEV1 (L)          | < 2           | 23 (12.23%) | 59 (31.38%) | 0.016 | 13 (27.08%) | 15 (31.25%) | 0.012 |
|                   | ≥ 2           | 14 (7.45%)  | 92 (48.94%) |        | 11 (22.92%) | 9 (18.75)  |        |
| BMI               | < 24          | 18 (9.57%)  | 96 (51.06%) | 0.132 | 11 (22.92%) | 11 (22.92%) | 0.011 |
|                   | ≥ 24          | 19 (10.11%) | 55 (29.26%) |        | 13 (27.08%) | 13 (27.08%) |        |
| Operative time (min) | < 150    | 11 (5.85%)  | 74 (39.36%) | 0.043 | 16 (33.33%) | 12 (25.00%) | 0.022 |
|                   | ≥ 150         | 26 (13.83%) | 77 (40.96%) |        | 8 (16.67%)  | 12 (25.00%) |        |
| Location of primary | Peripheral | 28 (14.89%) | 121 (64.36%) | 0.651 | 18 (37.50%) | 16 (33.33%) | 0.901 |
|                   | Central       | 9 (4.79%)   | 30 (15.96%) |        | 6 (12.50%)  | 8 (16.67%)  |        |
| Stage             | Early         | 21 (11.17%) | 113 (60.11%) | 0.042 | 8 (16.67%)  | 6 (12.50%)  | 0.056 |
|                   | Advanced      | 16 (8.51%)  | 38 (20.21%) |        | 16 (33.33%) | 18 (37.50%) |        |

BMI body mass index, FEV1 forced expiratory volume in 1 second, RLNI recurrent laryngeal nerve injury, PSM propensity scores matching

Risk factors of RLNI
Univariable analysis using PSM to preclude bias, identified dissection device, side of primary, FEV1, operative time and BMI as significantly associated with RLNI; age, gender, stage and location of the primary tumor were not similarly associated (Table 3). The significantly associated variables were then assessed by logistic regression model analysis, and all proved to be independent predictors of RLNI (Table 4).

Recovery time of RLNI
If either hoarseness or choking persisted, the neurological function of RLNI was considered not recovered. On the contrary, if both resolved, this completely recovered. With ongoing follow-up, nearly half of the RLNI patients in the non-energy-device group had recovered by two weeks. In contrast, only two patients had recovered in the energy-device group (P = 0.025). There was one patient in the non-energy-device group and five in
Table 4. Multivariable analysis of RLNI

|                          | HR (95% CI) | P value |
|--------------------------|------------|---------|
| Dissection device (energy vs. non-energy) | 3.576 (1.490–8.583) | 0.004 |
| Side of primary (left vs. right) | 0.175 (0.072–0.424) | < 0.001 |
| BMI (< 4 vs. ≥ 24) | 0.344 (0.147–0.801) | 0.013 |
| FEV1 (< 2 vs. ≥ 24) | 3.008 (1.307–6.927) | < 0.001 |
| Operative time (> 150min vs. ≤ 150min) | 0.328 (0.136–0.794) | 0.013 |

BMI: body mass index, HR: hazard ratio, CI: confidence interval, FEV1: forced expiratory volume in 1 second, RLNI: recurrent laryngeal nerve injury

Table 5. Comparison of the recovery time of RLNI between the two groups

|                  | Non-energy device (n=12) | Energy device (n=25) | P value |
|------------------|--------------------------|----------------------|---------|
| 2 weeks          | 5 (41.67%)               | 2 (8.00%)            | 0.025   |
| 1 month          | 3 (25.00%)               | 7 (28.00%)           | 0.998   |
| 3 months         | 3 (25.00%)               | 11 (44.00%)          | 0.306   |
| More than 6 months | 1 (8.33%)            | 5 (20.00%)           | 0.641   |

RLNI: recurrent laryngeal nerve injury

In the present study, patients in the non-energy-device group had significantly fewer RLNI than the energy-device group (Table 1). This was consistent with previous research indicating that the RLN could be paralyzed by thermal injury [10]. The results seem clear, but the procedure is difficult, because the anatomic detail around the RLNLNs is complex. The key to safe dissection of the RLNLNs is to identify and protect the motor branches of the RLN, which are the principal supply to the vocal cords [15]. Fortunately, the RLN's motor branches are larger in diameter with a constant course. These can be distinguished by the naked eye; the RLN function will not be affected when the sensory branches are separated [16]. However, some surgeons may be worried about chylothorax necessitating long duration of a chest tube, thinking that the routine use of the VSS can reduce postoperative chest tube drainage and earlier removal of the chest tube after MLND [10]. However, the present study showed that the duration of postoperative drainage in the non-energy-device group was not significantly longer than the energy-device group as long as the small vessels were carefully identified and clipped (Johnson, ER320).

All types of injury to the motor branches of the RLN can cause laryngeal muscle dysfunction, irrespective of thermal or non-thermal injury. Animal experiments showed that the RLN stimulation signal was not changed following continuous stimulation of the RLN at 40–55 °C for 60 s, but the signals were not received with RLN stimulation applied at 60 °C for 30 s, or 70 °C for 20 s [17]. This study also showed that when the temperature exceeded 60 °C, the RLN had been damaged [17]. Importantly, therefore, the temperature measured by Applewhite when the ultrasonic dissector was activated was approximately 115 °C, and the temperature generated by unipolar or bipolar coagulation was also approximately 100 °C [18]. Therefore, if the energy device touched the RLN during cutting or hemostasis, it would likely cause permanent RLNI for it always damaged the endoneurium [19]. Non-energy devices can also cause RLNI when scissors conduct vessels which reach the lymph nodes, and aspects of the operation, such as neoadjuvant therapy, intraoperative RLNLNs calcification and fusion, intraoperative tumor or metastatic lymph node invasion of the RLN and intrathoracic extensive adhesions or pleural cavity atresia, and precluded bias using PSM, we found that the dissection device, side of primary tumor, FEV1, operative time and BMI were significantly associated with RLNI (Table 3), and all of them were independent predictors of RLNI (Table 4). All of these factors were out of control by the surgeon except the specific type of dissection device. Therefore, improvement in dissection technique, and in this study, dissection technology, could facilitate attaining the goal of reducing RLNI.

Discussion

Mediastinal lymph node staging is an important component of the assessment and management of patients with operable NSCLC and is necessary to achieve complete resection [10]. In our study, every station of RLNLN had some degree of cancer metastasis and postoperative examination confirmed that the metastatic rate of RLNLNs was 5.2% (Table 2) for unforeseen N2 NSCLC patients. Although a relatively low percentage, the presence of metastatic RLNLNs had important implications in guiding postoperative treatment, controlling local recurrence rates, and judging patient prognosis. A 10-year cohort study showed patients that underwent MLND had longer survival than those with only mediastinal lymph node sampling (154.67 months vs. 124.67 months) [11]. Many thoracic surgeons are reluctant to proceed with dissection of RLNLNs due to its particular anatomical structure and the voice and swallowing changes incurred by its damage [12]. The RLN gives off sensory and motor branches along its course to the larynx, and these branches are woven into webs at the RLN looping point and surround the lymph nodes and adipose tissue [13, 14].

The risk factors of RLNI are varied. In our study, having excluded factors that might have influenced the technical

Yu and Ge BMC Surg (2021) 21:172

Page 5 of 7

the energy-device group that had not recovered by six months postoperatively, but the difference was not significant (P = 0.641, Table 5).
that may cause local hemorrhage due to non-vascular occlusive effects, resulting in stretch or clot compression when hemostasis. Schneider et al. [20] observed real-time RLN monitoring of animal experiments and found that when the RLN was stretched with a tensile force of 3000 mN, the signal received by the electromyography weakened by approximately 59%; when the RLN was compressed by 280 mmHg (37 KPa), the signal received by electromyography weakened by about 40%. However, most signals could recover again after releasing the traction or compression. Therefore, non-thermal RLNI is usually temporary.

Although it is very difficult to accurately assess RLNI without laryngoscopy [21], we relied on the clinically useful symptoms of hoarseness and choke as indicators of RLNI. Hoarseness was a common clinical manifestation of RLNI, and 79% of RLN with surgical trauma had hoarseness [22]. In Ewald’s study, he also equated hoarseness with RLNI [9]. Choke was mostly manifested as impairment of the superior laryngeal nerve (SLN) internal branch [23], but some patients with RLNI could also manifest as choke. The mechanism for this is the ipsilateral vocal cord loses its motor function and is fixed in the median or paramedian position after RLNI, and the vocal cord loses its barrier function. Additionally, both the RLN and the SLN originate from vagus nerve (VN) [24]. Before the external branch of the SLN enters the cricothyroid muscle, it divides a branch together with the RLN to control the thyroarytenoid muscle and lateral cricoarytenoid muscle [25]. There may be a traffic branch between RLN and SLN [26]. There is also direct communication between the posterior branches of the RLN and the internal branch of the SLN [27], that provides sensory innervation to the laryngeal mucosa [23]. Therefore, the two indicators were reasonable. Real-time RLN intraoperative monitoring may be an alternative, but it is not widely available to district hospitals and is difficult to perform routinely in clinical practice.

We also compared recovery time of RLNI between the two groups and found nearly half of the non-thermal RLNI had recovered within two weeks, while most thermal RLNI required three months for recovery (Table 5). This indicated that if RLNI had occurred, neurological function would recover sooner when using non-energy devices. There was more RLNI that did not recover by 6 months in the energy-device group, but this was not statistically significant, perhaps due to the relatively small overall number or short duration of follow-up.

The operative time in the energy-device group was significantly longer than the non-energy-device group. The important reason for this was that when energy devices were used to dissect lymph nodes and its surrounding tissues that contain the sensory branches of the RLN, these need to be carefully identified and transected without using energy, as thermal injury could be conducted to the motor branches. However, when using non-energy devices, after careful identification of the motor branches, the tissue bundles could be sealed directly with clips, and then be severed simultaneously, without causing RLN function damage.

This is a retrospective study and the determination of RLNI was dependent on clinical assessment of hoarseness and choking. A more precise technique using real-time RLN intraoperative monitoring would be optimal for future prospective research.

**Conclusion**

Every station of RLNLN had some degree of cancer metastasis in NSCLC patients and when dissecting RLNLNs, dissection device was an independent and artificially controlled predictor of RLNI. Using a non-energy device is a feasible method to protect the RLN as well as an improved recovery time of RLNI.

**Abbreviations**

NSCLC: Non-small cell lung cancer; SND: Systematic nodal dissection; RLN: Recurrent laryngeal nerve; RLNLNs: Recurrent laryngeal nerve lymph nodes; RLNI: Recurrent laryngeal nerve injury; HR: Hazard ratio; CI: Confidence interval; MLND: Mediastinal lymph node dissection; VSS: Vessel sealing system; VATS: Video-assisted thoracic surgery; BMI: Body mass index; FEV1: Forced expiratory volume in 1 s; SLN: Superior laryngeal nerve; RUL: Right upper lobe; RML: Right middle lobe; RLL: Right lower lobe; RUML: Right upper-middle lobe; RMLL: Right middle-lower lobe; LUL: Left upper lobe; LLL: Left lower lobe; PSM: Propensity scores matching.

**Acknowledgements**

The authors would like to express their gratitude to EditSprings (https://www.editsprings.com/) for the expert linguistic services provided.

**Authors’ contributions**

MHY collected and analysed data, interpreted the results and were involved in the initial study. MJG design the study and revised the manuscript. All authors have read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**

The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University and informed consent was obtained from patients included in the study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.
References

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
2. Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002;36:1–6.
3. Adachi H, Sakamaki K, Nishii T, Yamamoto T, Nagashima T, Ishikawa Y, et al. Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. J Thorac Oncol. 2012;7:895–9.
4. Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Eur J Cardiothorac Surg. 2013;44:e59–64.
5. Wen YS, Xi KK, Xi KS, Zhang RS, Wang GM, Huang ZR, et al. The number of resected lymph nodes is associated with the long-term survival outcome in patients with T2 N0 non-small cell lung cancer. Cancer Manag Res. 2018;10:6869–77.
6. Graham AN, Chan KJ, Pastorino U, Goldstraw P. Systematic nodal dissection in the intraintrathoracic staging of patients with non-small cell lung cancer. J Thorac Oncol. 1999;11:246–51.
7. Boussena JE, Aarts MJ, Dijkgraaf MGW, Annema JT, van den Broek FJC. Trends in mediastinal nodal staging and its impact on unfozseen N2 and survival in lung cancer. Eur Respir J. 2020. https://doi.org/10.1183/13993003.01549-2020.
8. Liu C, Pu Q, Guo C, Xiao Z, Mei J, Ma L, et al. Non-grasping en bloc mediastinal lymph node dissection for video-assisted thoracoscopic lung cancer surgery. BMC Surg. 2015;15:38.
9. Bollen EC, van Duin CJ, Theunissen PH, van Hof-Grootenboer BE, Blijham GH. Mediastinal lymph node dissection in resected lung cancer: morbidity and accuracy of staging. Ann Thorac Surg. 1993;55:961–6.
10. Watanabe A, Nakazawa J, Miyashita M, Harada R, Nakashima S, Mavatari T, et al. Thoracoscopic mediastinal lymph node dissection for lung cancer. Semin Thorac Cardiovasc Surg. 2012;24:68–73.
11. Shen-Tu Y, Mao F, Pan Y, Wang W, Zhang L, Zhang H, et al. Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: A 10-year cohort study. Medicine (Baltimore). 2017;96:e8356.
12. Amer K. The recurrent laryngeal nerves and the thoracic. Inc Media: CTSNet; 2017.
13. Asgharpour E, Maranillo E, Sanudo J, Pascual-Font A, Rodriguez-Niedenfuhr M, Valderama FJ, et al. Recurrent laryngeal nerve landmarks revisited. Head Neck. 2012;34:1246–6.
14. Cernea CR, Hojaj FC, De Carlucci Jr. D, Gotoda R, Plopper C, Vanderlei L, et al. Recurrent laryngeal nerve: a plexus rather than a nerve? Arch Otolaryngol Head Neck Surg. 2009;135:1098–102.
15. Soriano RM, Gupta V. Anatomy, head and neck, larynx nerves. Treasure Island (FL): StatPearls; 2020.
16. Amer K. Thoracoscopic mediastinal lymph node dissection for lung cancer. Semin Thorac Cardiovasc Surg. 2012;24:74–8.
17. LinYC, Dionigi G, Randolph GW, Lu IC, Chang PY, Tsai SY, et al. Electrophysiologic monitoring correlates of recurrent laryngeal nerve heat thermal injury in a porcine model. Laryngoscope. 2015;125:E283–290.
18. Applewhite MK, White MG, James BC, Abdulrasool L, Kaplan EL, Angelos P, et al. Ultrasonic, bipolar, and integrated energy devices: comparing heat spread in collateral tissues. J Surg Res. 2017;207:249–54.
19. Wu CW, Dionigi G, Sun H, Liu X, Kim HY, Hsiao PJ, et al. Intraoperative neuromonitoring for the early detection and prevention of RLN traction injury in thyroid surgery: a porcine model. Surgery. 2014;155:329–39.
20. Schneider R, Przybly J, Pliquett U, Hermann M, Wehner M, Pietsh UC, et al. A new vagal anchor electrode for real-time monitoring of the recurrent laryngeal nerve. Am J Surg. 2010;199:507–14.
21. Watanabe A, Koyanagi T, Obama T, Ohmae H, Mawatari T, Takahashi N, et al. Assessment of node dissection for clinical stage I primary lung cancer by VATS. Eur J Cardiothorac Surg. 2005;27:745–52.
22. Reiter R, Hoffmann TK, Pickhard A, Brossch K, Hoarsens causing and treatments. Dtsch Arztebl Int. 2015;112:529–37.
23. Miyachi A, Masuoka H, Nakayama A, Higashiyama T. Innervation of the cricothyroid muscle by extralaryngeal branches of the recurrent laryngeal nerve. Laryngoscope. 2016;126:1157–62.
24. Elsheikh E, Quriba AS, El-Anwar MW. Role changes after late recurrent laryngeal nerve identification thyroidectomy. J Voice. 2016;30:761–762 e769.
25. Henry BM, Pekala PA, Sanna R, Wsko J, Sanna S, Sengaith K, et al. The anastomoses of the recurrent laryngeal nerve in the larynx: a meta-analysis and systematic review. J Voice. 2017;31:495–503.
26. Naidu L, Lazarus L, Partab P, Satyapal KS. Laryngeal nerve “anastomoses.” Folia Morphol (Warsz). 2014;73:30–6.
27. Sanudo JR, Maranillo E, Leon X, Mirapeix RM, Orus C, Quer M. Anatomical study of anastomoses between the laryngeal nerves. Laryngoscope. 1999;109:983–7.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.